2022年首场肿瘤学学术盛会美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO-GI）将于美国时间1月20～22日以线上会议的形式举办，为诸位肿瘤领域学者带来消化道肿瘤最新进展。本次大会依旧有三种类型的交流，按重要性排序分别是：口头汇报（Oral Abstract）、摘要速递（Rapid Abstract）和壁报交流（Poster）。从学术委员会角度看，oral和rapid abstract两个口头汇报类别就是最重要的研究，可能对临床实践带来影响。近日，口头报告（Oral Abstract）和摘要速递（Rapid Abstract）专场题目已于ASCO官网公布，覆盖免疫、靶向和局部治疗等多种内容。【肿瘤资讯】特将两个会场题目整理如下，一起来领略学术的魅力吧！
口头报告
食管癌和胃癌专场（Cancers of the Esophagus and Stomach）
III期JCOG1109 NExT研究：在局部晚期食管癌新辅助治疗中，双药化疗联合方案 vs放疗-化疗联合方案
A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.
识别上消化道肿瘤复发产生的新抗原特征
Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.
CheckMate 649研究的扩展疗效、安全性和亚组分析：纳武利尤单抗联合化疗vs 化疗作为晚期胃癌/胃食管交界处癌/食管腺癌（GC/GEJC/EAC）一线治疗
Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649.
III期KEYNOTE-590研究：晚期食管癌一线治疗中，比较帕博利珠单抗联合化疗 vs 化疗的长期疗效、安全性和生活质量结果
First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.
胰腺癌、小肠癌和肝胆管癌专场（Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract）
III期Trybeca-1研究：在晚期胰腺癌患者二线治疗中，eryaspase联合化疗 vs 单独化疗疗效
Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441)
III期TOPAZ-1研究：在晚期胆道癌患者中，度伐利尤单抗联合吉西他滨及顺铂的随机、双盲、安慰剂对照试验
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
III期HIMALAYA研究：在不可切除肝细胞癌患者一线治疗中，tremelimumab +度伐利尤单抗的随机、开放标签、多中心试验
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
III期、多中心、随机对照试验：仑伐替尼联合经动脉化疗栓塞术用于晚期肝细胞癌的一线治疗（中山大学第一附属医院 彭振维教授）
Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial.
结肠癌、直肠癌和肛门癌专场（Cancers of the Colon, Rectum, and Anus）
II期CheckMate 9X8研究：纳武利尤单抗联合5-氟尿嘧啶/亚叶酸/奥沙利铂(mFOLFOX6)/贝伐珠单抗 vs mFOLFOX6/贝伐珠单抗用于转移性结直肠癌的一线治疗结果
Nivolumab (NIVO) + 5-fluorouracil /leucovorin /oxaliplatin (mFOLFOX6) /bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.
来自日本CIRCULATE的GALAXY观察性研究：结直肠癌患者辅助治疗中循环肿瘤DNA动力学与临床结局的相关性
Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan
III期JCOG1018研究(RESPECT)：在老年转移性结直肠癌患者中，mFOLFOX7或CapeOX联合贝伐珠单抗 vs 5-FU/l-LV或卡培他滨联合贝伐珠单抗的初始治疗疗效
A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT).
11项试验的ACCENT/IDEA汇总分析：需要接受奥沙利铂辅助化疗6个月的III期结肠癌患者，早期治疗中断和早期奥沙利铂停药对于预后影响
Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.
摘要速递
食管癌和胃癌专场（Cancers of the Esophagus and Stomach）
Trastuzumab deruxtecan(T-DXd；DS-8201)治疗HER2阳性晚期胃或胃食管交界处(GEJ)腺癌患者：一项随机、多中心、开放性、II期研究(DESTINY-Gastric01)的最终总生存期(OS)结果
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
III期KEYNOTE-062研究结果更新：帕博利珠单抗联合或不联合化疗 vs 单纯化疗治疗PD-L1阳性晚期胃或胃食管交界处腺癌患者
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.
II期GERCOR NEONIPIGA研究：纳武利尤单抗联合伊匹木单抗新辅助治疗和纳武利尤单抗辅助治疗局部微卫星高度不稳定(MSI)/错配修复缺陷(dMMR)食管胃腺癌(OGA)患者
Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.
DELIVER试验（JACCRO GC-08）：肠道微生物等宿主相关生物标志物预测纳武利尤单抗在晚期胃癌中的毒性
Host-related biomarkers including gut microbiome to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).
一项Ib/II期、多中心、开放性研究：PD-1/CTLA-4双特异性抗体AK104联合化疗作为晚期胃癌(G)或胃食管交界癌(GEJ)一线治疗（季加孚教授 北京大学肿瘤医院）
A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.
胰腺癌、小肠癌和肝胆管癌专场（Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract）
KRYSTAL-1研究：adagrasib(MRTX849)在不可切除或转移性胰腺癌(PDAC)和携带KRAS G12C突变的其他胃肠道(GI)肿瘤患者中的活性和安全性结果更新
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS G12C mutation.
日本临床肿瘤组研究(JCOG1213) 的随机III期研究：依托泊苷联合顺铂 vs 伊立替康联合顺铂治疗晚期消化系统神经内分泌癌
Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213).
在根治性胆道癌切除术后，S-1辅助治疗 vs 观察的III期试验(JCOG1202：ASCOT)
Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT)
III期KEYNOTE-394研究：帕博利珠单抗+最佳支持治疗 vs安慰剂 + 最佳支持治疗作为晚期肝细胞癌(HCC)亚洲患者的二线治疗（秦叔逵教授 南京金陵医院）
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
CISPD3研究：信迪利单抗联合改良folfrinox方案与单用folfrinox方案治疗中国转移性和复发性胰腺癌患者的随机III期试验（梁廷波教授 浙江大学医学院附属第一医院）
Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial.
结肠癌、直肠癌和肛门癌专场（Cancers of the Colon, Rectum, and Anus）
康奈替尼（encorafenib）+西妥昔单抗+纳武利尤单抗用于微卫星稳定的BRAF V600E突变转移性结直肠癌患者的I/II期试验
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.
II期GERCOR NIPICOL研究： 高度微卫星不稳定/错配修复缺陷(MSI/dMMR)转移性结直肠癌(mCRC)患者接受1年纳武利尤单抗+伊匹单抗治疗的长期随访结果
One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.
一项多中心、随机对照试验：机器人手术 vs 腹腔镜手术治疗中低位直肠癌(REAL)的短期结局（许剑民教授 复旦大学附属中山医院）
Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): Short-term outcomes of a multicenter randomized controlled trial.
瑞戈非尼+帕博利珠单抗用于难治性微卫星稳定结直肠癌(MSSCRC)的I/II期研究
Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC).
PD-1阻断疗法用于错配修复缺陷(dMMR)的局部晚期直肠癌
PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer.
一项II期、多中心、开放性研究(DESTINY-CRC01)：Trastuzumab deruxtecan(T-DXd；DS-8201)治疗HER2阳性的转移性结直肠癌(mCRC)患者的最终结果
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
扫码关注专栏，获取更多ASCO GI信息
排版编辑：肿瘤资讯-Jo
苏公网安备32059002004080号
